CGT commercial trajectories are set years before approval — and every development decision is an access decision.
Feature|Articles|September 23, 2026
Shaping the Future of Market Access: Q&A with Jen Norton
Author(s)Jen Norton
Market access is now too complex for historical analogues — and AI is the only tool that can model what comes next.
Advertisement
Advertisement
How to help drug manufacturers navigate complex market factors to reach more patients is a challenge nearly every company faces. That’s why market access strategies continue to be top of mind in the industry. Recently, Pharmaceutical Executive caught up with Jen Norton, a veteran in market access who recently joined EVERSANA.
Related to this article
The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.
Inizio's Elaine Ferguson on why AI value requires deconstructing workflows task by task — aligning each to the right combination of talent and technology.
Advertisement
Advertisement